赛莱科西布诱导的急性泛化脱血性 pustulosis:不常见的和未被认可的副作用
Abul Hasan Shadali Abdul Khader1, Meenu Singh1
1University of Utah Medical Center, Salt Lake City, Utah, USA.
EXCLI journal
|March 15, 2024
概括
切莱科西布是一种常见的关节炎药物,很少会导致急性全身外血性肺炎 (AGEP),一种严重的皮肤反应. 及时停止使用诸如赛莱科西布之类的NSAID对于患者的康复至关重要.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 切莱科西布是一种选择性COX-2抑制剂,是骨关节炎和类风湿性关节炎等炎症状况的第一线止痛药.
- 虽然在降低胃肠道风险方面更受欢迎,但塞莱科克西布具有潜在的不良影响,包括器官毒性和严重的皮肤反应.
- 急性全身脱血性瘤发病 (AGEP) 是一种罕见但严重的药物诱导的皮肤反应,其特征是,发烧和白细胞瘤发病.
研究的目的:
- 报告一例Celecoxib诱导的AGEP病例,强调NSAIDs作为潜在的触发因素.
- 提高医疗保健专业人员对这种罕见但严重的药物不良反应的认识.
- 强调早期诊断和药物戒断对于管理塞莱科西布诱导的AGEP的重要性.
主要方法:
- 一个44岁的女性的病例介绍,她患有快速进展的疹.
- 临床评估,皮肤活检用于对AGEP的组织病理学确认.
- 审查患者的药物史,确定最近对关节炎的赛莱科克西布使用情况.
主要成果:
- 患者呈现出广泛,痛苦和的疹和白细胞瘤.
- 组织病理学证实了AGEP,患者的病史显示最近摄入了塞莱科克西布.
- 用类固醇治疗和中止NSAID治疗导致皮疹在三天内显著改善.
结论:
- 这一案例强调了NSAIDs,包括赛莱科克西布,可以诱导AGEP.
- 早期识别和停止违规的NSAID对于管理赛莱科西布诱导的AGEP至关重要.
- 虽然AGEP通常是可以管理的,但可能会产生严重的后果,需要提高临床警.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
118
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
118
Drugs for Treatment of Ulcerative Colitis in IBD
139
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
139
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
163
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
163
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Allergic Drug Reactions
839
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
839
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
434
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
434


